Literature DB >> 32071061

Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa.

Kevin D McCormick1, Kerri J Penrose2, Chanson J Brumme3,4, P Richard Harrigan4, Raquel V Viana5, John W Mellors2, Urvi M Parikh2, Carole L Wallis5.   

Abstract

Etravirine (ETR) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) used in treatment-experienced individuals. Genotypic resistance test-interpretation systems can predict ETR resistance; however, genotype-based algorithms are derived primarily from HIV-1 subtype B and may not accurately predict resistance in non-B subtypes. The frequency of ETR resistance among recombinant subtype C HIV-1 and the accuracy of genotypic interpretation systems were investigated. HIV-1LAI containing full-length RT from HIV-1 subtype C-positive individuals experiencing virologic failure (>10,000 copies/ml and >1 NNRTI resistance-associated mutation) were phenotyped for ETR susceptibility. Fold change (FC) was calculated against a composite 50% effective concentration (EC50) from treatment-naive individuals and three classifications were assigned: (i) <2.9-FC, susceptible; (ii) ≥2.9- to 10-FC, partially resistant; and (iii) >10-FC, fully resistant. The Stanford HIVdb-v8.4 was used for genotype predictions merging the susceptible/potential low-level and low-level/intermediate groups for 3 × 3 comparison. Fifty-four of a hundred samples had reduced ETR susceptibility (≥2.9-FC). The FC correlated with HIVdb-v8.4 (Spearman's rho = 0.62; P < 0.0001); however, 44% of samples were partially (1 resistance classification difference) and 4% completely discordant (2 resistance classification differences). Of the 34 samples with an FC of >10, 26 were HIVdb-v8.4 classified as low-intermediate resistant. Mutations L100I, Y181C, or M230L were present in 27/34 (79%) of samples with an FC of >10 but only in 2/46 (4%) of samples with an FC of <2.9. No other mutations were associated with ETR resistance. Viruses containing the mutation K65R were associated with reduced ETR susceptibility, but 65R reversions did not increase ETR susceptibility. Therefore, genotypic interpretation systems were found to misclassify ETR susceptibility in HIV-1 subtype C samples. Modifications to genotypic algorithms are needed to improve the prediction of ETR resistance for the HIV-1 subtype C.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  ETR; HIVdb; NNRTI; etravirine; genotyping; phenotyping; subtype C; third line

Mesh:

Substances:

Year:  2020        PMID: 32071061      PMCID: PMC7179637          DOI: 10.1128/AAC.02101-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.

Authors:  Anne Derache; Carole L Wallis; Saran Vardhanabhuti; John Bartlett; Nagalingeswaran Kumarasamy; David Katzenstein
Journal:  J Infect Dis       Date:  2015-07-14       Impact factor: 5.226

2.  Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa.

Authors:  Kevin D McCormick; Kerri J Penrose; Chanson J Brumme; P Richard Harrigan; Raquel V Viana; John W Mellors; Urvi M Parikh; Carole L Wallis
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.

Authors:  Johan Vingerhoets; Steven Nijs; Lotke Tambuyzer; Annemie Hoogstoel; David Anderson; Gaston Picchio
Journal:  Antivir Ther       Date:  2012-08-07

4.  Characteristics and early outcomes of children and adolescents treated with darunavir/ritonavir-, raltegravir- or etravirine-containing antiretroviral therapy in the Western Cape Province of South Africa.

Authors:  J Nuttall; V Pillay
Journal:  S Afr Med J       Date:  2018-02-01

5.  TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.

Authors:  Johan Vingerhoets; Hilde Azijn; Els Fransen; Inky De Baere; Liesbet Smeulders; Dirk Jochmans; Koen Andries; Rudi Pauwels; Marie-Pierre de Béthune
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.

Authors:  Duncan T Njenda; Shambhu G Aralaguppe; Kamalendra Singh; Rohit Rao; Anders Sönnerborg; Stefan G Sarafianos; Ujjwal Neogi
Journal:  J Antimicrob Chemother       Date:  2018-10-01       Impact factor: 5.790

7.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christine Katlama; Arend Moll; William Towner; Benoit Trottier; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Benny Baeten; Greet Beets; Rekha Sinha; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

8.  Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.

Authors:  Carole L Wallis; Maria A Papathanasopoulos; Shabir Lakhi; Etienne Karita; Anatoli Kamali; Pontiano Kaleebu; Eduard Sanders; Omu Anzala; Linda-Gail Bekker; Gwynn Stevens; Tobias F Rinke de Wit; Wendy Stevens
Journal:  J Virol Methods       Date:  2009-11-14       Impact factor: 2.014

9.  The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Tommy F Liu; Soo-Yon Rhee; Mark Kiuchi; Stephane Hue; Deenan Pillay; Robert W Shafer
Journal:  Bioinformatics       Date:  2009-03-20       Impact factor: 6.937

10.  Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity.

Authors:  Eva Agneskog; Piotr Nowak; Catharina Maijgren Steffensson; Maria Casadellà; Marc Noguera-Julian; Roger Paredes; Clas F R Källander; Anders Sönnerborg
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

View more
  1 in total

1.  Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa.

Authors:  Kevin D McCormick; Kerri J Penrose; Chanson J Brumme; P Richard Harrigan; Raquel V Viana; John W Mellors; Urvi M Parikh; Carole L Wallis
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.